Catalyst Dossier · compiled by Celia 🧫

Gilead Sciences, Inc. (GILD)

Biological Products, (No Diagnostic Substances) · market cap $153.7B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Gilead Sciences (GILD) is a large-cap biopharmaceutical company (~$154B market cap) headquartered in Foster City, CA, with an established franchise in HIV/AIDS, hepatitis, and oncology generating $29.4B in 2025 revenue and $8.5B net income. The company carries $15.9B net debt but maintains $7.6B cash and a broad late-stage pipeline spanning oncology (Trodelvy, sacituzumab govitecan), HIV prevention (lenacapavir), and several Phase 3 and Phase 2 programs. The near-term catalyst calendar is dense, with a high-importance Phase 3 readout for Eribulin Mesylate and Sacituzumab Govitecan in late 2026/early 2027.

The catalyst path

2026-07-15 (est.)Phase 2 · Emtricitabine/tenofovir disoproxil fumarate (F/TDF)imp 7/10
2026-08-06Earningsimp 5/10
2026-08-15 (est.)Phase 2 · Domvanalimabimp 7/10
2026-09-15 (est.)Phase 2 · TAFimp 7/10
2026-10-15 (est.)Phase 2 · Sacituzumab Govitecan-hziyimp 7/10
2026-12-15 (est.)Phase 3 · Eribulin Mesylate Injectionimp 9/10
2026-12-15 (est.)Phase 2 · anitocabtagene-autoleucelimp 7/10
2027-01-01 (est.)Partnershipimp 7/10

Pipeline

Asset	Phase	Indication
MTX	Phase 3	Rheumatoid Arthritis
Trodelvy	Approved	Triple-Negative Breast Cancer
Lenacapavir	Phase 3	HIV Prevention
Magrolimab	Phase 3	Myelodysplastic Syndrome
Cetuximab	Phase 2	Solid Tumor
GS-9451	Phase 2	Hepatitis C, Chronic
KTE-C19	Phase 2	Refractory Diffuse Large B Cell Lymphoma
Zimberelimab	Phase 3	Head and Neck Squamous Cell Carcinoma
Ruxolitinib	Phase 2	Myelofibrosis
Stribild	Phase 3	Acquired Immunodeficiency Syndrome
D/C/F/TAF	Phase 2	Acquired Immunodeficiency Syndrome
GS-9876	Phase 2	Rheumatoid Arthritis
Sacituzumab Govitecan (SG)	Phase 3	Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Paclitaxel	Phase 3	Locally Advanced or Unresectable Metastatic Breast Cancer
Baseline DRV- containing ARV regimen	Phase 3	HIV-1
Tegobuvir (GS-9190)	Phase 2	Hepatitis C, Chronic
seladelpar 5-10 mg	Phase 3	Primary Biliary Cholangitis
Pembrolizumab	Phase 2	Non-small Cell Lung Cancer
RTV	Phase 3	Acquired Immunodeficiency Syndrome
Seladelpar	Phase 3	Primary Biliary Cholangitis

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.